The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Trial ID
ACTRN12605000150640
Ethics application status
Approved
Date submitted
10/08/2005
Date registered
15/08/2005
Date last updated
15/08/2005
Type of registration
Prospectively registered

Titles & IDs
Public title
Is regional anaesthesia associated with postoperative cognitive deficit? A prospective randomised controlled trial.
Scientific title
The prospective randomised controlled phase III GRAIL Trial will consider patients receiving general anaesthesia compared to those receiving regional anaesthesia to undergo extracorporeal shock wave lithotripsy for the treatment of kidney stones and will evaluate whether there is any difference in the incidence of postoperative cognitive dysfunction (POCD) in the short and medium term.
Universal Trial Number (UTN)
Trial acronym
The GRAIL Trial
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Post Operative Cognitive Dysfunction (POCD) 241 0
Condition category
Condition code
Mental Health 272 272 0 0
Studies of normal psychology, cognitive function and behaviour
Anaesthesiology 273 273 0 0
Other anaesthesiology

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
To study patients undergoing a single surgical treatment: extracorporeal shock wave lithotripsy (ESWL) for treatment of kidney stones. General anaesthesia will consist of routine clinical practice using midazolam/fentanyl/propofol/laryngeal mask/spontaneous respiration of air and oxygen. Regional anaesthesia will conform to current practice consisting of #25 gauge spinal needle and 0.5% heavy spinal marcaine. Patients will complete a neuropyschological test battery preoperatively, 7 days and 3 months postoperatively and a short test version at discharge.
Intervention code [1] 157 0
Treatment: Other
Comparator / control treatment
Control group
Active

Outcomes
Primary outcome [1] 322 0
Freqeuncy of POCD
Timepoint [1] 322 0
At 7 days and 3 months postoperatively.
Secondary outcome [1] 722 0
Quality of life
Timepoint [1] 722 0
At 3 months.

Eligibility
Key inclusion criteria
Patients who are scheduled for elective ESWL, do not have neurological deficit, give written informed consent and have no contraindication to neuropsychological testing. The patients must reside in accessible proximity to the hospital to enable investigators to administer testing at home.
Minimum age
55 Years
Maximum age
Not stated
Gender
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Pre-existing neurological or neurovascualr disease (eg. stroke); 2. Score of less than 24 on the Mini Mental State Examination (MMSE); 3. Anticipated difficulty with neuropsychologcail assessment such as English not being the prime language, blindness, deafness; 4. Associated medical problems that may lead to significant complications and subsequent loss to follow-up (ASA Physical Status IV or higher); 5. Contraindication to spinal anaesthesia (eg. anti-coagulation therapy or bleeding tendency); 6. Body Mass Index (BMI) greater than 35.

Study design
Purpose of the study
Prevention
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Sealed envelope to anaesthetist immediately prior to procedure.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Random allocation sequence will be generated by computer software PC_PLAN. The restriction method will be random permuted blocks
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint(s)
Safety
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)

Funding & Sponsors
Funding source category [1] 328 0
Other Collaborative groups
Name [1] 328 0
Australia and New Zealand College of Anaesthetists
Address [1] 328 0
Country [1] 328 0
Primary sponsor type
Individual
Name
Dr. Brendan Silbert
Address
Country
Secondary sponsor category [1] 259 0
Individual
Name [1] 259 0
A/Prof. David Scott
Address [1] 259 0
Country [1] 259 0
Secondary sponsor category [2] 260 0
Individual
Name [2] 260 0
A/Prof. Paul Maruff
Address [2] 260 0
Country [2] 260 0
Secondary sponsor category [3] 261 0
Individual
Name [3] 261 0
Ms. Lis Evered
Address [3] 261 0
Country [3] 261 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 1263 0
St. Vincent's Hospital Melbourne
Ethics committee address [1] 1263 0
Ethics committee country [1] 1263 0
Australia
Date submitted for ethics approval [1] 1263 0
Approval date [1] 1263 0
Ethics approval number [1] 1263 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 35792 0
Address 35792 0
Country 35792 0
Phone 35792 0
Fax 35792 0
Email 35792 0
Contact person for public queries
Name 9346 0
Dr. Brendan Silbert
Address 9346 0
Department of Anaesthesia
St. Vincent's Hospital
PO Box 2900
Fitzroy VIC 3065
Country 9346 0
Australia
Phone 9346 0
+61 3 92884253
Fax 9346 0
+61 3 92884255
Email 9346 0
silberbs@svhm.org.au
Contact person for scientific queries
Name 274 0
Ms. Lis Evered
Address 274 0
Department of Anaesthesia
St. Vincent's Hospital
PO Box 2900
Fitzroy VIC 3065
Country 274 0
Australia
Phone 274 0
+61 3 92882251
Fax 274 0
+61 3 92884255
Email 274 0
everedl@svhm.org.au